Global Hunter Securities Starts Raptor Pharmaceuticals (RPTP) at Buy; DR Cysteamine - A Potentially Game-Changing Therapy
Tweet
Share
E-mailGet Alerts RPTP Hot Sheet
Price: $9.00 --0%
Rating Summary:
6 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
6 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Global Hunter Securities initiates coverage on Raptor Pharmaceuticals (NASDAQ: RPTP) with a Buy. PT $6.
Global analyst said, "Although the company’s near-term success is tied to the success of DR Cysteamine in cystinosis, we believe the drug can provide several other shots on goal in larger market opportunities such as Huntington’s disease and Non-Alcoholic Steatohepatitis (NASH). We view DR Cysteamine in Huntington’s disease, Convivia in ALDH2 deficiency and Tezampanel in thrombotic disorder as call options given the programs’ early stages of development. We see upcoming milestones such as Phase III DR Cysteamine data in cystinosis in Q2, completion of patient enrollment in the Phase II Huntington’s study in Q3, initiation of a Phase II study in NASH in H2 and a concurrent US/EU 505(b)2 filing in cystinosis in early 2012 as potential catalysts to boost shares. We view RPTP as an undervalued investment opportunity based on decreased development risk, numerous shots on goal and attractive valuation."
For more ratings news on Raptor Pharmaceuticals click here and for the rating history of Raptor Pharmaceuticals click here.
Shares of Raptor Pharmaceuticals closed at $3.32 yesterday.
Global analyst said, "Although the company’s near-term success is tied to the success of DR Cysteamine in cystinosis, we believe the drug can provide several other shots on goal in larger market opportunities such as Huntington’s disease and Non-Alcoholic Steatohepatitis (NASH). We view DR Cysteamine in Huntington’s disease, Convivia in ALDH2 deficiency and Tezampanel in thrombotic disorder as call options given the programs’ early stages of development. We see upcoming milestones such as Phase III DR Cysteamine data in cystinosis in Q2, completion of patient enrollment in the Phase II Huntington’s study in Q3, initiation of a Phase II study in NASH in H2 and a concurrent US/EU 505(b)2 filing in cystinosis in early 2012 as potential catalysts to boost shares. We view RPTP as an undervalued investment opportunity based on decreased development risk, numerous shots on goal and attractive valuation."
For more ratings news on Raptor Pharmaceuticals click here and for the rating history of Raptor Pharmaceuticals click here.
Shares of Raptor Pharmaceuticals closed at $3.32 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- Raymond James Starts Polaryx Therapeutics (PLYX) at Strong Buy
- JPMorgan Assumes salesforce.com (CRM) at Overweight, 'Overblown Concerns'
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
